Skip to main content

Table 1 Bivariate relationships between substance use disorders (SUD) and interferon (IFN) completion and response rates among veterans with available hepatitis C (HCV) genotypes

From: Interferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disorders

  SUD- Group SUD+ Group    
  N % N % OR 95% CI p
Known vs. Unknown Genotype        
   Not available 42 12.0% 52 11.2% 1.08 0.70–1.67 0.718
   Available 308 88.0% 413 88.8%    
Genotypes 2 & 3        
Completed ≥ 22 Weeks of IFN        
   No 29 26.9% 56 32.0% 0.78 0.46 – 1.33 0.359
   Yes 79 73.1% 119 68.0%    
End of Treatment Response (ETR)        
   Not available 8 7.4% 9 5.1% 1.38 0.51 – 3.74 0.528
   Available 71 65.7% 110 62.9%    
No Response 14 13.0% 15 8.6% 1.56 0.70 – 3.46 0.276
Response 57 52.8% 95 54.3%    
Sustained Viral Response (SVR)        
   Not available 4 3.7% 8 4.6% 0.79 0.23 – 2.73 0.705
   Available 61 56.5% 96 54.9%    
No Response 15 13.9% 24 13.7% 0.98 0.47 – 2.06 0.954
Response 46 42.6% 72 41.1%    
Genotypes 1 & 4        
Completed ≥ 46 Weeks of IFN        
   No 121 60.5% 143 60.1% 1.02 0.69 – 1.49 0.929
   Yes 79 39.5% 95 39.9%    
End of Treatment Response (ETR)        
   Not available 9 8.3% 19 10.9% 0.51 0.22 – 1.21 0.124
   Available 70 64.8% 76 43.4%    
No Response 21 19.4% 17 9.7% 1.49 0.71 – 3.13 0.294
Response 49 45.4% 59 33.7%    
Sustained Viral Response (SVR)        
   Not available 3 2.8% 4 2.3% 1.01 0.22 – 4.69 0.991
   Available 55 50.9% 74 42.3%    
No Response 23 21.3% 21 12.0% 1.81 0.87 – 3.79 0.111
Response 32 29.6% 53 30.3%    
  1. CI = Confidence interval, ETR = End of treatment response, IFN = Interferon, OR = Odds ratio, SUD = Substance use disorder, SVR = Sustained viral response. ORs reflect the SUD+ Group compared with the SUD- Group. The SUD+ Group includes veterans with a history of substance use disorder. The SUD- Group includes veterans with no history of substance use disorder. Completion rates are based on all patients with available genotypes. Response rates are based on all patients with known HCV genotypes who initiated IFN therapy. Patients were considered non-responders if they failed to clear the virus or if they were lost to follow-up (e.g., unavailable ETR or SVR).